Mavacamten (MYK-461) | Friends of Cancer Research

You are here

Mavacamten (MYK-461)

Sponsor: 
MyoKardia
Indication: 
Treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Year: 
2020
Date: 
Jul 23rd
FDA Status: 
Designation Granted